Clinical Efficacy of Cefoperazone-Sulbactam versus Piperacillin-Tazobactam in the Treatment of Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia
Chia-Hung Chen,Chih-Yen Tu,Wei-Chih Chen,Li-Kuo Kuo,Yao-Tung Wang,Pin-Kuei Fu,Shih-Chi Ku,Wen-Feng Fang,Chin-Ming Chen,Chih-Cheng Lai
DOI: https://doi.org/10.2147/IDR.S313828
2021-06-16
Infection and Drug Resistance
Abstract:Chia-Hung Chen, 1 Chih-Yen Tu, 1 Wei-Chih Chen, 2 Li-Kuo Kuo, 3 Yao-Tung Wang, 4 Pin-Kuei Fu, 5 Shih-Chi Ku, 6 Wen-Feng Fang, 7 Chin-Ming Chen, 8 Chih-Cheng Lai 9 1 Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan; 2 Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan; 3 Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan; 4 Division of Pulmonary Medicine, Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan; 5 Department of Critical Care Medicine, Taichung Veterans General Hospital, Taichung, Taiwan; 6 Division of Chest Medicine, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan; 7 Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan; 8 Department of Intensive Care Medicine, Chi Mei Medical Center, Tainan, Taiwan; 9 Department of Internal Medicine, Kaohsiung Veterans General Hospital, Tainan Branch, Tainan, Taiwan Correspondence: Chih-Cheng Lai Email Objective: The aim of this study was to compare the usefulness of cefoperazone-sulbactam and that of piperacillin-tazobactam in the treatment of hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP). Methods: This retrospective study included the adult patients receiving cefoperazone-sulbactam or piperacillin-tazobactam against HAP/VAP in nine hospitals in Taiwan from March 1, 2018 to May 30, 2019. Primary outcome was clinical cure rate. Results: A total of 410 patients were enrolled. Among them, 209 patients received cefoperazone-sulbactam and 201 patients received piperacillin-tazobactam. Overall, cefoperazone-sulbactam group had similar distribution of age, sex, or SOFA scores as piperacillin-tazobactam group. However, cefoperazone-sulbactam had higher comorbidity score and disease severity than piperacillin-tazobactam group (Charlson score: 6.5 ± 2.9 vs 5.7 ± 2.7, p < 0.001; APACHE II score: 21.4 ± 6.2 vs 19.3 ± 6.0, p = 0.002). Regarding clinical outcomes, no significant difference in clinical cure and failure rates was observed between cefoperazone-sulbactam and piperacillin-tazobactam group (clinical cure rate: 80.9% vs 80.1% and clinical failure rate: 17.2% vs 18.4%, p = 0.943). Moreover, no significant difference in clinical effectiveness and ineffectiveness rates was observed between cefoperazone-sulbactam and piperacillin-tazobactam group (clinical effective rate: 80.9% vs 80.6% and clinical ineffective rate: 17.7% vs 18.9%, p = 0.711). The all-cause mortality rates of the cefoperazone-sulbactam and piperacillin-tazobactam groups were similar (23.9% vs 20.9%, p = 0.48). After adjustment of Charlson score and APACHE II score, the similarities in these clinical outcomes did not change in overall patients and patients with HAP or VAP. Conclusion: For treating adult patients with nosocomial pneumonia, cefoperazone-sulbactam was as effective as piperacillin-tazobactam. Keywords: cefoperazone-sulbactam, hospital-acquired pneumonia, piperacillin-tazobactam, ventilator-associated pneumonia Hospital-acquired pneumonia (HAP) is the most common type of hospital-acquired infections, 1 , 2 and ventilator-associated pneumonia (VAP) is also a common type of infection in intensive care units (ICUs). 3 Importantly, both HAP and VAP are associated with high morbidity, mortality, and health-care expenditure. 2–4 Although administration of appropriate antibiotics remains the most important treatment for patients with HAP/VAP, 2 , 3 the emergence of antibiotic resistance among causative pathogens—multidrug resistant organisms (MDROs)—has largely limited therapeutic options. Gram-negative bacilli (GNB), such as Pseudomonas aeruginosa and Enterobacteriaceae , play an important role in HAP/VAP, 5–7 and many kinds of antibiotic-resistance mechanism have been detected among these pathogens. 8 , 9 Therefore, a combination of ß-lactam and ß-lactamase inhibitor as a broad-spectrum antibiotic was recommended as one of therapeutic options in the treatment of HAP/VAP. Cefoperazone-sulbactam is one of combinations of ß-lactam and ß-lactamase inh -Abstract Truncated-
pharmacology & pharmacy,infectious diseases